ScoreWhy is Marksans Pharma Ltd ?
1
High Management Efficiency with a high ROE of 15.04%
2
The company is Net-Debt Free
3
With a growth in Net Profit of 6.97%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 2 consecutive quarters
- PAT(9M) At Rs 418.50 cr has Grown at 65.13%
- NET SALES(9M) At Rs 2,451.34 cr has Grown at 21.94%
- PBDIT(Q) Highest at Rs 213.03 cr.
4
High Institutional Holdings at 23.66%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating performance in long term as well as near term
- Along with generating 96.03% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Marksans Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Marksans Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Marksans Pharma
96.03%
2.24
42.86%
Sensex
-9.06%
-0.67
13.50%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
17.87%
EBIT Growth (5y)
14.58%
EBIT to Interest (avg)
28.58
Debt to EBITDA (avg)
0.40
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
1.05
Tax Ratio
24.51%
Dividend Payout Ratio
9.53%
Pledged Shares
0
Institutional Holding
23.66%
ROCE (avg)
26.15%
ROE (avg)
15.04%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
29
Industry P/E
37
Price to Book Value
4.98
EV to EBIT
23.50
EV to EBITDA
20.19
EV to Capital Employed
6.06
EV to Sales
4.54
PEG Ratio
0.61
Dividend Yield
0.27%
ROCE (Latest)
21.13%
ROE (Latest)
13.82%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
PAT(9M)
At Rs 418.50 cr has Grown at 65.13%
NET SALES(9M)
At Rs 2,451.34 cr has Grown at 21.94%
PBDIT(Q)
Highest at Rs 213.03 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 25.34%
PBT LESS OI(Q)
At Rs 181.17 cr has Grown at 51.6% (vs previous 4Q average
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 989.65 cr
EPS(Q)
Highest at Rs 3.47
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Marksans Pharma
Operating Profit (PBDIT) - Quarterly
Highest at Rs 213.03 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 25.34% and Grown
each quarter in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 181.17 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 181.17 cr has Grown at 51.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 119.51 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 157.17 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 157.17 cr has Grown at 50.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 104.48 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Latest six months
At Rs 1,696.91 cr has Grown at 27.74%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 3.47
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 989.65 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
